

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: AI/ML Innovations Inc. (the "Issuer").

Trading Symbol: AIML

Number of Outstanding Listed Securities: 34,930,270

Date: 2/9/2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued to advance its business operations on multiple fronts. Its majority owned subsidiary, Health Gauge, was active in developing additional business relationships and continued development work of its apps and cloud solutions.

The issuer's minority-owned subsidiary, Tech2Heal, also continued the development work on its Remote Patient Monitoring Platform (Alakin) and its flagship Qookka mental wellness platform.

2. Provide a general overview and discussion of the activities of management.

During the month, management has been primarily engaged in the improvement of Health Gauge's technology, including the continued development work on upgrades to its mobile apps and cloud-based platform to improve efficiency and accuracy and to add new feature sets, along with FDA regulatory work for compliancy as a Class 2 Medical Device in the US and Canada. It also furthered its discussions with potential channel partners and other potential users of the HG technology. Consulting work with MedWatch continued by Health Gauge towards the advancement of MedWatch's blood glucose monitoring device.

Management was engaged with the Issuer's auditor regarding completion of the Year End Audited Financial Statements of the Corporation. Management reported that it made an application to the British Columbia Securities Commission to approve a management case trade order ("MCTO") under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"), which, if granted, will prohibit trading in the securities of the Company by the Chief Executive Officer and Chief Financial Officer of the Company until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted.

Subsequently, management reported that the Issuer did not file its audited annual financial statements, management's discussion and analysis and related CEO and CFO certifications for the financial year ended April 30, 2022 (the "Required Filings") by the filing deadline of August 28, 2022, and as a result is in default of its obligations under Part 4 of National Instrument 51-102 Continuous Disclosure Obligations.

As previously announced on August 19, 2022 (the "Announcement"), the Company applied to the British Columbia Securities Commission (the "BCSC") for a management cease trade order (the "MCTO"), which would restrict all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company. The BCSC issued the MCTO on August 30, 2022. The MCTO does not generally affect the ability of shareholders who are not insiders of the Company to trade their securities.

The Company and its auditor continue to work diligently toward completing the Required Filings, and expect to remedy the default by filing the Required Filings on or before October 28, 2022.

3. Describe and provide details of any new products or services developed or offered.
None.
4. Describe and provide details of any products or services that were discontinued.
None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
None.
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
None.
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
None.
8. Describe the acquisition of new customers or loss of customers.
None.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
None.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
None.
11. Report on any labour disputes and resolutions of those disputes if applicable.
None.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
None.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
None.
14. Provide details of any securities issued and options or warrants granted.
None.

15. Provide details of any loans to or by Related Persons.
None.
16. Provide details of any changes in directors, officers or committee members.
None.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There is a growing awareness and acceptance amongst the public, healthcare providers, insurers/payors, and regulators towards the use of digital and virtual healthcare in general, with mental healthcare making up an increasing component of that. This trend is expected to continue at double digit growth rates globally for the next several years. Its acceptance has been expedited by the CV-19 pandemic as patients were discouraged from face-to-face medical intervention in all but the most dire of circumstances. The general public has grown to understand the ease and convenience of digital healthcare as a result and healthcare payors understand that the deployment of digital health solutions both improves outcomes and reduces costs. Governments across Europe are implementing laws requiring payors to cover the cost of digital mental health therapy to the same extent as conventional methods.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated 2/9/2022

Tim Daniels
Name of Director or Senior
Officer

/S/ "Tim Daniels"
Signature
Executive Chairman
Official Capacity

Issuer Details Name of Issuer AI/ML Innovations Inc.	For Month End July 2022	Date of Report YY/MM/D 22/9/2
Issuer Address Suite 203, 645 Fort St.		
City/Province/Postal Code Victoria, BC V8W 1G2	Issuer Fax No.	Issuer Telephone No. (778) 405-0882
Contact Name Tim Daniels	Contact Position Director	Contact Telephone No. 250 483-5650
Contact Email Address tim.daniels@aiml-innovations.com	Web Site Address aiml-innovations.com	